Novogen, Yale University preclinical data

In a mouse model of ovarian cancer, 100 mg/kg intraperitoneal Cantrixil for 17 days significantly reduced tumor burden by >90% vs. vehicle-treated controls (p<0.01). Additionally, Cantrixil plus cisplatin led to significantly greater reductions in tumor burden compared to cisplatin alone and to vehicle-treated controls (p=0.002 and p=0.004, respectively). Data were presented at the American Association for Cancer Research meeting in Philadelphia. ...